US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
biotech · Pediatric acute-onset neuropsychiatric syndrome (PANS) · acute hereditary angioedema attacks · MAZE
Maze Therapeutics
Maze Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2018 Founded
152 Employees
Public company Type
MAZE · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 8
- Drugs
- 12
- Patents
- 60
Maze Therapeutics pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Maze Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
human normal immunoglobulin
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Maze Therapeutics's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.
-
Development asset linked to Maze Therapeutics in public FDA and regional records.